TITLE

Budesonide/Formoterol: A Viewpoint by Michael Roth1,2

AUTHOR(S)
Michael Roth, Paul W.
PUB. DATE
February 2004
SOURCE
Drugs;2004, Vol. 64 Issue 4, p443
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
This article presents views of the author on formoterol. Corticosteroids combined with long-acting J32-agonists, for example budesonide/formoterol, have been suggested for the treatment of inflammatory lung diseases, including asthma and chronic obstructive pulmonary disease (COPD). The incidence of both diseases is increasing worldwide, but there is no effective therapy available. With regard to COPD, cessation of smoking or corticosteroid or p2-agonist therapy can only slow down the progression of the disease, but can neither stop nor revert it.
ACCESSION #
12285079

 

Related Articles

  • Long-acting beta2-agonists in asthma: not so SMART? Currie, Graeme P.; Lee, Daniel K. C.; Lipworth, Brian J. // Drug Safety;2006, Vol. 29 Issue 8, p647 

    Asthma is a worldwide chronic disorder that is characterised by airway inflammation and hyper-responsiveness, which results in intermittent airflow obstruction and subsequent perception of symptoms and exacerbations. Inhaled corticosteroids are a fundamental component in the prevention of the...

  • Budesonide/Formoterol: In Chronic Obstructive Pulmonary Disease. Reynolds, Neil A.; Perry, Caroline M.; Keating, Gillian M. // Drugs;2004, Vol. 64 Issue 4, p431 

    ▴ Budesonide/formoterol is a fixed-dose combination of the corticosteroid budesonide and the long-acting β[sub 2]-agonist formoterol, and is inhaled via the Turbuhaler[sup ®] device. ▴ In two large, randomised, double-blind, 12-month studies, patients with severe chronic...

  • Budesonide/Formoterol: A Viewpoint by Paul W. Jones. Jones, Paul W. // Drugs;2004, Vol. 64 Issue 4, p444 

    Budesonide/formoterol is a fixed-dose combination of the corticosteroid budesonide and formoterol, a long-acting J32-agonist, inhaled as a dry powder. Current guidelines for chronic obstructive pulmonary disease (COPD) recommend a long-acting p2-agonist for patients whose symptoms are not...

  • Uplifting times for COPD. Halpin, David M.G. // Primary Care Respiratory Journal;Dec2008, Vol. 17 Issue 4, p197 

    The article focuses on the randomised double-blind placebo-controlled study which examined the effects of tiotropium on chronic obstructive pulmonary disease (COPD) patients. Researchers allowed patients to take other respiratory medications including long-acting beta-agonists (LABA) and inhaled...

  • New Pharmacologic Perspectives in Pneumology: Beclomethasone-Formoterol Extrafine. Paggiaro, Pierluigi // Open Respiratory Medicine Journal;2009, Vol. 3, p38 

    International asthma guidelines have recently focused on the concept of «control», which is the main outcome to reach and maintain in the long term management. Asthma control is associated with several positive consequences, both in terms of quality of life and pathophysiological findings....

  • COPD combination therapy questioned.  // Independent Nurse;11/2/2009, p15 

    The article discusses a Dutch study concerning the addition of long-acting beta-agonists (LABAs) to corticosteroid therapy for chronic obstructive pulmonary disease (COPD). The findings of the study negate an analysis of the Toxoplasmosis, Rubella, Cytomegalovirus and Herpes Simplex (TORCH)...

  • Long-Acting β-Agonists With vs Without Inhaled Corticosteroids for COPD. Suissa, Samy; Ernst, Pierre // JAMA: Journal of the American Medical Association;1/20/2015, Vol. 313 Issue 3, p305 

    A letter to the editor is presented in response to an observational study led by Andrea S. Gershon, M.D., which evaluates the long-term outcomes linked with use of long-acting beta-agonists along with inhaled corticosteroids in chronic obstructive pulmonary disease.

  • Long-Acting β-Agonists With vs Without Inhaled Corticosteroids for COPD. Gershon, Andrea S.; Campitelli, Michael A.; Stanbrook, Matthew B. // JAMA: Journal of the American Medical Association;1/20/2015, Vol. 313 Issue 3, p205 

    A response from the author of a study on the long-term outcomes linked with use of long-acting beta-agonists along with inhaled corticosteroids in chronic obstructive pulmonary disease is presented.

  • 2008 - Review: Long-acting beta-agonists do not increase risk for asthma-related hospitalization in patients taking inhaled corticosteroids. Shafazand, Shirin // ACP Journal Club;3/17/2009, Vol. 150 Issue 3, p3 

    The article deliberates on the safety of using concomitant therapy with long-acting beta-agonists (LABAs) in asthma patients who are taking inhaled corticosteroids (ICSs). Research conducted reveals that asthma patients who are taking ICSs, concomitant therapy with long-acting beta-agonists does...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics